CJC-1295: DAC vs No-DAC, Evidence and Safety Risks
CJC-1295 guide covering DAC vs no-DAC terminology, GH and IGF-1 evidence, FDA safety concerns, side effects, and peptide-market claims.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone, or GHRH. It is popular in peptide-market discussions because it can raise growth hormone and IGF-1 biomarkers in human studies. That does not make it an approved therapy, and it does not prove the anti-aging, fat-loss, recovery or muscle-building claims often attached to it.
The useful way to read CJC-1295 is to separate biomarker evidence from outcome evidence. Published human studies show prolonged GH and IGF-1 stimulation. They do not show that consumer use improves body composition, sleep, skin, injury recovery, longevity or performance in a clinically proven way.
CJC-1295 also has a regulatory safety problem. FDA lists CJC-1295 among bulk drug substances that may present significant safety risks when compounded, including immunogenicity concerns, peptide impurity and API characterization complexity, and serious adverse events such as increased heart rate and systemic vasodilatory reaction.
Quick Evidence Snapshot
| Question | Current answer |
|---|---|
| What is it? | A long-acting GHRH analog developed to stimulate GH release |
| Main biomarker effect | Increased GH and downstream IGF-1 in small human studies |
| Approved indication | None in the United States |
| Best human evidence | Short pharmacology studies in healthy adults |
| Outcome evidence | Not established for anti-aging, muscle gain, fat loss or recovery |
| Main safety concern | Limited clinical data plus FDA-identified compounding safety risks |
| Sport status | Prohibited under WADA growth hormone-releasing factor rules |
DAC vs No-DAC: The Naming Problem
CJC-1295 is often discussed in two versions: "with DAC" and "no-DAC." DAC means drug affinity complex. The DAC design allows the molecule to bind albumin, which extends exposure and explains why the published CJC-1295 studies measured GH and IGF-1 elevation for days rather than minutes.
The no-DAC label is less clean. Many products marketed as CJC-1295 no-DAC are better understood as modified GRF(1-29), a shorter-acting GHRH analog. In practical terms, that means two products may be sold under similar names while having different pharmacokinetics and different risk profiles.
This is why PeptideStat treats CJC-1295 as a growth hormone peptide topic rather than a simple supplement-style product. Small naming differences can change half-life, exposure, stacking logic and adverse-effect risk. For background on half-life and accumulation, see the peptide half-life guide and the accumulation calculator.
What Human Studies Actually Show
The strongest CJC-1295 evidence is pharmacology evidence. In a healthy-adult study, a single injection produced dose-dependent increases in mean plasma GH for six days or more and mean plasma IGF-1 for nine to eleven days. The PubMed abstract reports GH increases of about 2-fold to 10-fold and IGF-1 increases of about 1.5-fold to 3-fold.
A second human analysis found that pulsatile GH secretion persisted during continuous stimulation by CJC-1295. That finding matters because natural GH is pulsatile, and sustained elevation without any pulsatility would raise a different biological question. Still, preserving pulses is not the same as proving meaningful clinical benefit.
A third study examined serum protein profile changes after CJC-1295 exposure. That paper supports the idea that CJC-1295 activates the GH/IGF-1 axis, but it does not establish consumer endpoints such as improved recovery, lower fat mass, higher lean mass or longer healthspan.
| Evidence type | What it supports | What it does not prove |
|---|---|---|
| Human GH and IGF-1 pharmacology | CJC-1295 can stimulate the GH/IGF-1 axis | Long-term safety or clinical benefit |
| GH pulsatility analysis | GH pulses can persist during stimulation | That use is physiologic or low risk in real-world users |
| Serum protein profiling | Downstream biological effects are measurable | Anti-aging, recovery or performance outcomes |
| Animal and receptor work | Mechanism and albumin-binding design | Human efficacy claims |
This is the same evidence distinction used in PeptideStat's tesamorelin guide. Tesamorelin has an approved label for a narrow HIV-associated visceral fat indication. CJC-1295 does not have a comparable label or large outcome dataset.
CJC-1295 vs Sermorelin, Ipamorelin and Tesamorelin
CJC-1295 is often stacked or compared with other GH-axis peptides. The comparison is useful, but only if mechanism and regulatory status stay clear.
| Compound | Main pathway | Status in this context | Practical distinction |
|---|---|---|---|
| CJC-1295 | GHRH receptor analog, long-acting with DAC | Research-only, no approved indication | Raises GH and IGF-1 biomarkers for days in small studies |
| Sermorelin | GHRH analog | Older clinical history, not a broad anti-aging approval | Shorter-acting GHRH-pathway comparator |
| Ipamorelin | Ghrelin receptor / GHSR secretagogue | Research-only | Different receptor pathway, often paired in peptide-market protocols |
| Tesamorelin | GHRH analog | FDA-approved for HIV-associated lipodystrophy | Strongest regulated evidence in this group |
For more context, read ipamorelin vs sermorelin, sermorelin complete guide, and the tesamorelin evidence review. The short version is that "raises GH" is not enough. Approval status, endpoint, trial population, half-life and safety monitoring all matter.
Safety: What To Take Seriously
GH-axis manipulation is not a cosmetic shortcut. Raising GH and IGF-1 can be biologically meaningful, which is the reason the peptide is interesting and also the reason casual claims should be treated carefully.
Potential concerns include:
- Injection-site reactions and product sterility risk, especially outside regulated pharmacy channels.
- Fluid retention, joint discomfort, numbness or carpal-tunnel-like symptoms, which are classically associated with excessive GH activity.
- Glucose and insulin-resistance concerns in people predisposed to diabetes.
- Elevated heart rate or vasodilatory reactions, which FDA has identified in connection with CJC-1295 safety concerns.
- Uncertain long-term consequences of repeated GH/IGF-1 stimulation in populations not studied in trials.
- Anti-doping violations for athletes subject to WADA or aligned rules.
The FDA compounding page is especially relevant because it does not merely say "unapproved." It identifies CJC-1295 as a substance that may present significant safety risks when compounded. The FDA concerns include immunogenicity for certain routes, peptide impurity issues, API characterization complexity and limited clinical data.
That does not mean every claimed CJC-1295 adverse event is proven. It means the available evidence is not enough to treat widespread non-approved use as established or low risk.
Why Research-Market Claims Overreach
Most online CJC-1295 claims skip a step. They move from "GH and IGF-1 rise" to "therefore muscle, fat loss, recovery, sleep and anti-aging improve." That leap is not supported by the published human CJC-1295 studies.
The stronger framing is:
- Human evidence indicates CJC-1295 can stimulate GH and IGF-1 biomarkers.
- The published human studies are small and pharmacology-focused.
- Direct outcome evidence for consumer claims remains limited or absent.
- Safety is not characterized to the standard expected of an approved drug.
- Product quality is a separate risk when the source is a research-chemical vendor.
Readers interested in handling and quality boundaries should also review the peptide storage guide, because storage advice does not solve sterility, identity or impurity problems in unapproved injectable products. Storage and reconstitution technique cannot turn an unregulated product into an FDA-approved medicine.
What Better Evidence Would Need
A stronger CJC-1295 evidence base would need to look different from the published pharmacology record. Useful trials would enroll the population being claimed, define a clinical endpoint in advance, measure harms over months or years, and compare CJC-1295 with placebo or a relevant approved option. For body-composition claims, that would mean imaging-based fat and lean-mass outcomes, strength or function measures, glucose monitoring and adverse-event tracking. For recovery claims, it would mean injury-specific outcomes rather than general wellness scoring.
Until those data exist, the conservative conclusion is not that CJC-1295 "does nothing." The better conclusion is narrower: CJC-1295 has human biomarker activity, but the clinical value and risk balance for common consumer claims remain unproven.
Bottom Line
CJC-1295 has real pharmacology evidence. It can raise GH and IGF-1 in humans, and its DAC design explains the long exposure that makes it distinct from shorter-acting GHRH analogs.
The same evidence also shows the limit. CJC-1295 is not FDA approved, does not have robust clinical outcome data for common peptide-market claims, and is flagged by FDA for compounding-related safety concerns. Treat it as a research-only GH-axis compound, not as a proven anti-aging, recovery or body composition tool.
References
Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Gaudreau P, et al. Human growth hormone-releasing factor albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
FDA. Human Drug Compounding.
World Anti-Doping Agency. The Prohibited List.